In the case of emerging tumours, these inflammatory ILC2s may be going through similar genotypic changes and, based on mounting evidence50,68,75,76, it is also highly likely that the plasticity of inflammatory ILC2s may extend to a Th1 shift, since these cells respond to IL-1 and IL-12 stimulation with cell activation, heightened T-bet expression, increased Th1 molecule production and lowered expression of GATA3. This evidence concerns the gene IL1B and neoplasm.